Tingting Deng, Jianwen Liang, Cuiju Yan, Mengqian Ni, Huiling Xiang, Chunyan Li, Jinjing Ou, Qingguang Lin, Lixian Liu, Guoxue Tang, Rongzhen Luo, Xin An, Yi Gao, Xi Lin
{"title":"开发并验证基于超声波的放射组学模型,用于预测乳腺癌患者的种系 BRCA 基因突变。","authors":"Tingting Deng, Jianwen Liang, Cuiju Yan, Mengqian Ni, Huiling Xiang, Chunyan Li, Jinjing Ou, Qingguang Lin, Lixian Liu, Guoxue Tang, Rongzhen Luo, Xin An, Yi Gao, Xi Lin","doi":"10.1186/s40644-024-00676-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Identifying breast cancer (BC) patients with germline breast cancer susceptibility gene (gBRCA) mutation is important. The current criteria for germline testing for BC remain controversial. This study aimed to develop a nomogram incorporating ultrasound radiomic features and clinicopathological factors to predict gBRCA mutations in patients with BC.</p><p><strong>Materials and methods: </strong>In this retrospective study, 497 women with BC who underwent gBRCA genetic testing from March 2013 to May 2022 were included, including 348 for training (84 with and 264 without a gBRCA mutation) and 149 for validation(36 patients with and 113 without a gBRCA mutation). Factors associated with gBRCA mutations were identified to establish a clinicopathological model. Radiomics features were extracted from the intratumoral and peritumoral regions (3 mm and 5 mm) of each image. The least absolute shrinkage and selection operator regression algorithm was used to select the features and logistic regression analysis was used to construct three imaging models. Finally, a nomogram that combined clinicopathological and radiomics features was developed. The models were evaluated based on the area under the receiver operating characteristic curve (AUC), calibration, and clinical usefulness.</p><p><strong>Results: </strong>Age at diagnosis, family history of BC, personal history of other BRCA-related cancers, and human epidermal growth factor receptor 2 status were independent predictors of the clinicopathological model. The AUC of the imaging radiomics model combining intratumoral and peritumoral 3 mm areas in the validation set was 0.783 (95% confidence interval [CI]: 0.702-0.862), which showed the best performance among three imaging models. The nomogram yielded better performance than the clinicopathological model in validation sets (AUC: 0.824 [0.755-0.894] versus 0.659 [0.563-0.755], p = 0.007).</p><p><strong>Conclusion: </strong>The nomogram based on ultrasound images and clinicopathological factors performs well in predicting gBRCA mutations in BC patients and may help to improve clinical decisions about genetic testing.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905812/pdf/","citationCount":"0","resultStr":"{\"title\":\"Development and validation of ultrasound-based radiomics model to predict germline BRCA mutations in patients with breast cancer.\",\"authors\":\"Tingting Deng, Jianwen Liang, Cuiju Yan, Mengqian Ni, Huiling Xiang, Chunyan Li, Jinjing Ou, Qingguang Lin, Lixian Liu, Guoxue Tang, Rongzhen Luo, Xin An, Yi Gao, Xi Lin\",\"doi\":\"10.1186/s40644-024-00676-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Identifying breast cancer (BC) patients with germline breast cancer susceptibility gene (gBRCA) mutation is important. The current criteria for germline testing for BC remain controversial. This study aimed to develop a nomogram incorporating ultrasound radiomic features and clinicopathological factors to predict gBRCA mutations in patients with BC.</p><p><strong>Materials and methods: </strong>In this retrospective study, 497 women with BC who underwent gBRCA genetic testing from March 2013 to May 2022 were included, including 348 for training (84 with and 264 without a gBRCA mutation) and 149 for validation(36 patients with and 113 without a gBRCA mutation). Factors associated with gBRCA mutations were identified to establish a clinicopathological model. Radiomics features were extracted from the intratumoral and peritumoral regions (3 mm and 5 mm) of each image. The least absolute shrinkage and selection operator regression algorithm was used to select the features and logistic regression analysis was used to construct three imaging models. Finally, a nomogram that combined clinicopathological and radiomics features was developed. The models were evaluated based on the area under the receiver operating characteristic curve (AUC), calibration, and clinical usefulness.</p><p><strong>Results: </strong>Age at diagnosis, family history of BC, personal history of other BRCA-related cancers, and human epidermal growth factor receptor 2 status were independent predictors of the clinicopathological model. The AUC of the imaging radiomics model combining intratumoral and peritumoral 3 mm areas in the validation set was 0.783 (95% confidence interval [CI]: 0.702-0.862), which showed the best performance among three imaging models. The nomogram yielded better performance than the clinicopathological model in validation sets (AUC: 0.824 [0.755-0.894] versus 0.659 [0.563-0.755], p = 0.007).</p><p><strong>Conclusion: </strong>The nomogram based on ultrasound images and clinicopathological factors performs well in predicting gBRCA mutations in BC patients and may help to improve clinical decisions about genetic testing.</p>\",\"PeriodicalId\":9548,\"journal\":{\"name\":\"Cancer Imaging\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-02-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905812/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40644-024-00676-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40644-024-00676-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:识别乳腺癌(BC)患者的种系乳腺癌易感基因(gBRCA)突变非常重要。目前,乳腺癌种系检测的标准仍存在争议。本研究旨在结合超声放射学特征和临床病理学因素制定一个提名图,以预测 BC 患者的 gBRCA 基因突变:在这项回顾性研究中,纳入了2013年3月至2022年5月期间接受gBRCA基因检测的497名BC女性患者,其中348人用于训练(84人有gBRCA突变,264人无gBRCA突变),149人用于验证(36名患者有gBRCA突变,113名患者无gBRCA突变)。确定了与 gBRCA 基因突变相关的因素,以建立临床病理模型。从每张图像的瘤内和瘤周区域(3 毫米和 5 毫米)提取放射组学特征。使用最小绝对收缩和选择算子回归算法选择特征,并使用逻辑回归分析构建三个成像模型。最后,结合临床病理学和放射组学特征,建立了一个提名图。根据接收者操作特征曲线下面积(AUC)、校准和临床实用性对模型进行了评估:结果:诊断时的年龄、BC家族史、其他BRCA相关癌症的个人病史以及人表皮生长因子受体2状态是临床病理模型的独立预测因素。在验证集中,结合瘤内和瘤周3毫米区域的影像放射组学模型的AUC为0.783(95%置信区间[CI]:0.702-0.862),在三种影像模型中表现最佳。在验证集中,提名图比临床病理模型的性能更好(AUC:0.824 [0.755-0.894] 对 0.659 [0.563-0.755],P = 0.007):基于超声图像和临床病理因素的提名图在预测 BC 患者的 gBRCA 基因突变方面表现良好,可能有助于改善基因检测的临床决策。
Development and validation of ultrasound-based radiomics model to predict germline BRCA mutations in patients with breast cancer.
Background: Identifying breast cancer (BC) patients with germline breast cancer susceptibility gene (gBRCA) mutation is important. The current criteria for germline testing for BC remain controversial. This study aimed to develop a nomogram incorporating ultrasound radiomic features and clinicopathological factors to predict gBRCA mutations in patients with BC.
Materials and methods: In this retrospective study, 497 women with BC who underwent gBRCA genetic testing from March 2013 to May 2022 were included, including 348 for training (84 with and 264 without a gBRCA mutation) and 149 for validation(36 patients with and 113 without a gBRCA mutation). Factors associated with gBRCA mutations were identified to establish a clinicopathological model. Radiomics features were extracted from the intratumoral and peritumoral regions (3 mm and 5 mm) of each image. The least absolute shrinkage and selection operator regression algorithm was used to select the features and logistic regression analysis was used to construct three imaging models. Finally, a nomogram that combined clinicopathological and radiomics features was developed. The models were evaluated based on the area under the receiver operating characteristic curve (AUC), calibration, and clinical usefulness.
Results: Age at diagnosis, family history of BC, personal history of other BRCA-related cancers, and human epidermal growth factor receptor 2 status were independent predictors of the clinicopathological model. The AUC of the imaging radiomics model combining intratumoral and peritumoral 3 mm areas in the validation set was 0.783 (95% confidence interval [CI]: 0.702-0.862), which showed the best performance among three imaging models. The nomogram yielded better performance than the clinicopathological model in validation sets (AUC: 0.824 [0.755-0.894] versus 0.659 [0.563-0.755], p = 0.007).
Conclusion: The nomogram based on ultrasound images and clinicopathological factors performs well in predicting gBRCA mutations in BC patients and may help to improve clinical decisions about genetic testing.
Cancer ImagingONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
7.00
自引率
0.00%
发文量
66
审稿时长
>12 weeks
期刊介绍:
Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology.
The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include:
Breast Imaging
Chest
Complications of treatment
Ear, Nose & Throat
Gastrointestinal
Hepatobiliary & Pancreatic
Imaging biomarkers
Interventional
Lymphoma
Measurement of tumour response
Molecular functional imaging
Musculoskeletal
Neuro oncology
Nuclear Medicine
Paediatric.